The Patent Finder

Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors

Pharmacyclics, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 4 of these applications claim priority to application 13/003,811, filed May 25, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 9,107,924Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors
In force
 · High confidence
Pharmacyclics LLCIn force
High confidence
US 9,795,605Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors
In force
 · High confidence
Pharmacyclics LLCIn force
High confidence
US 9,278,100Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors
In force
 · Medium confidence
Pharmacyclics LLCIn force
Medium confidence
US 8,883,803Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors
Grace period ended Nov 11, 2026 · lapse expected
 · Low confidence
Pharmacyclics LLCGrace period ended Nov 11, 2026
lapse expected
Low confidence
Application 13/003,811Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors
Abandoned
Abandoned Dec 11, 2016
Pharmacyclics LLCAbandonedAbandoned Dec 11, 2016
Application 15/292,614Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors
Abandoned
Abandoned Mar 26, 2019
Pharmacyclics LLCAbandonedAbandoned Mar 26, 2019
Application 15/790,725Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors
Abandoned
Abandoned Mar 1, 2019
Pharmacyclics LLCAbandonedAbandoned Mar 1, 2019
Application 16/361,069Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors
Abandoned
Abandoned Sep 11, 2021
Pharmacyclics LLCAbandonedAbandoned Sep 11, 2021
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Pharmacyclics, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited